Non-pegylated liposomal doxorubicin (Myocet®) in patients with poor-risk aggressive B-cell non-Hodgkin lymphoma

Leukemia and Lymphoma

Volumn 52, Issue 7, 2011, Pages 1222-1229

  Dell'Olio, Matteo ^a   Potito Scalzulli, Rosario ^a   Sanpaolo, Grazia ^a   Nobile, Michele ^a   Saverio Mantuano, Francesco ^a   La Sala, Antonio ^a   D'Arena, Giovanni ^a   Miraglia, Eustachio ^b   Lucania, Anna ^c   Mastrullo, Lucia ^c   Nicola, Cascavilla ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b 'San Giovanni Bosco' Hospital   (Italy)

^c San Gennaro Hospital   (Italy)

Author keywords

B cell lymphoma; cardiac toxicity; non pegylated liposomal doxorubicin; poor risk patients

Indexed keywords

ANTIBIOTIC AGENT; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BACKACHE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CONSTIPATION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; FOLLOW UP; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL ADMISSION; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; ORAL MUCOSITIS; OVERALL SURVIVAL; PARESTHESIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PYREXIA IDIOPATHICA; RISK ASSESSMENT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM STAGING; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 79959582374     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.572321     Document Type: Article

References (35)

1. Brincker H, Pedersen NT, Bendix-Hansen K, Johansen P. Non-Hodgkin's lymphoma subtypes over time in an unselected population of 646 patients: a study of clinicopathological data and incidence based on a review using the REAL-classification. Leuk Lymphoma 2000;39:531-541. (Pubitemid 32162392)
2. Muller A, Ihorst G, Mertelsmann R, EngelhardtM. Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution and etiology. Ann Haematol 1999;84:1-12.
3. The Non-Hodgkin's Lymphoma Classification Project. Effect of age on the characteristics and clinical behavior of non- Hodgkin's lymphoma patients. Ann Oncol 1997;8:973-978.
4. Bastion Y, Blay JY, Divine M, Brice P, Bordessoule D, Sebban C. Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival-a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years. J Clin Oncol 1997; 15:2945-2953. (Pubitemid 27330023)
5. Vose JM, Armitage JO, Weisenburger DD, Bierman PJ, Sorensen S, Hutchins M. The importance of age in survival of patients treated with chemotherapy for aggressive non- Hodgkin's lymphoma. J Clin Oncol 1988;6:1838-1844. (Pubitemid 19089066)
6. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non- Hodgkin's lymphoma. N Engl J Med 1993;328:1002-1006. (Pubitemid 23095683)
7. Gordon LI, Harrington D, Andersen J, Colgan J, Glick J, Neiman R. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 1992;327:1342-1349.
8. Armitage JO, Fyfe MAE, Lewis J. Long term remission durabilityand functional status of patients treated for diffuse histiocytic lymphoma with the CHOP regimen. J Clin Oncol 1984;2:898-902. (Pubitemid 14037767)
9. Jerkeman M, Anderson H, Cavallin-Stahl E, et al. CHOP versus MACOP-B in aggressive lymphoma - a Nordic Lymphoma Group randomised trial. Ann Oncol 1999;10: 1079-1086. (Pubitemid 29482463)
10. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large- B-cell lymphoma. N Engl J Med 2002;346:235-242. (Pubitemid 34438862)
11. Armitage JO, Potter JF. Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: increased complications with advancing age. J Am Geriatr Soc 1984;32:269-273. (Pubitemid 14135573)
12. Sonneveld P, de Ridder M, van der Lelie H, et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol 1995;13:2530-2539.
13. Meyer R, Browman G, Samosh M, et al. Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma. J Clin Oncol 1995;13:2386-2393.
14. Elliott P. Pathogenesis of cardiotoxicity induced by anthracyclines. Semin Oncol 2006;33:2-7. (Pubitemid 43866214)
15. Johnson SA. Anthracycline-induced cardiotoxicity in adult hematologic malignancies. Semin Oncol 2006;33(Suppl. 8):S22-S27.
16. Gianni L, Herman HE, Lipshults SE, Minotti G, Sarvazyan N, Sawyer DB. Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol 2008;26:3777-3784.
17. Visani G, Isidori A. Nonpegylated liposomal doxorubicin in the treatment of B-cell non-Hodgkin's lymphoma: where we stand. Expert Rev Anticancer Ther 2009;9:357-363.
18. Ostro MJ. Liposomes: from the bench to the marketplace - doxorubicin as an example. In: Fidler IJ, Lopez-Berestein G, editors. Liposomes in the therapy of infectious diseases and cancer. Alan Liss: New York; 1989. pp 155-163.
19. Mayer LD, Bally MB, Cullis PR, Wilson SL, Emerman JT. Comparison of free and liposome-encapsulated doxorubicin tumor drug uptake and antitumor efficacy in the SC115 murine mammary tumor. Cancer Lett 1990;53:183-190. (Pubitemid 20323611)
20. van Dalen EC, Michiels EMC, Caron HN, Kremer LCM.Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev 2010;(5): CD005006.
21. Batist G, Ramakriskan G, Rao CS, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized multicenter trial of metastatic breast cancer. J Clin Oncol 2001;19:1444-1454. (Pubitemid 32202552)
22. Harris L, Batist G, Belt R, et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 2002;94:25-36. (Pubitemid 34049039)
23. Anderlini P, Benjamin RS, Wong FC, et al. Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. J Clin Oncol 1995;13:2827-2834.
24. Swerdlow SH, Campo E, Harris NL, et al.WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008.
25. Carbone PP, Kaplan HS, Musshoff K. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971;31:1860-1861.
26. Levine AM, Tulpule A, Espina B, et al. Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response. J Clin Oncol 2004;22:2662-2670. (Pubitemid 41103754)
27. Cheson BD, Horning SJ, Coiffier B, et al. Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas. J Clin Oncol 1999;17:1244-1253. (Pubitemid 29162950)
28. Tulpule A, Espina BM, Berman N, et al. Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. Clin Lymphoma Myeloma 2006;7:59-64. (Pubitemid 44322771)
29. Rigacci L, Mappa S, Nassi L, et al. Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines. Hematol Oncol 2007;25:198-203.
30. Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109:1857-1861. (Pubitemid 46348180)
31. O'Brien MER, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYXTM/Doxil1) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004;15:440-449. (Pubitemid 38444547)
32. Allen TM, Martin FJ. Advantages of liposomal delivery systems for anthracyclines. Semin Oncol 2004;31: 5-15. (Pubitemid 40023239)
33. Swenson CE, Bolcsak LE, Batist G, et al. Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer. Anticancer Drugs 2003;14:239-246. (Pubitemid 36418944)
34. Ewer MS, Ewer MS, Martin FJ, et al. Cardiac safety of liposomal anthracyclines. Semin Oncol 2004;31:161-181. (Pubitemid 40023246)
35. Limat S, Demesmay K, Voillat L, et al. Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma. Ann Oncol 2003;14:277-281. (Pubitemid 36305441)